AU6556194A - Method for screening for receptor agonists - Google Patents

Method for screening for receptor agonists

Info

Publication number
AU6556194A
AU6556194A AU65561/94A AU6556194A AU6556194A AU 6556194 A AU6556194 A AU 6556194A AU 65561/94 A AU65561/94 A AU 65561/94A AU 6556194 A AU6556194 A AU 6556194A AU 6556194 A AU6556194 A AU 6556194A
Authority
AU
Australia
Prior art keywords
receptor
promoter
cell
region
agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU65561/94A
Other languages
English (en)
Inventor
Ronald P McDonnell
Maty Tzukerman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ligand Pharmaceuticals Inc
Original Assignee
Ligand Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ligand Pharmaceuticals Inc filed Critical Ligand Pharmaceuticals Inc
Publication of AU6556194A publication Critical patent/AU6556194A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU65561/94A 1993-04-07 1994-04-06 Method for screening for receptor agonists Abandoned AU6556194A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4580793A 1993-04-07 1993-04-07
US045807 1993-04-07
US17975094A 1994-01-10 1994-01-10
US179750 1994-01-10
PCT/US1994/003795 WO1994023068A1 (fr) 1993-04-07 1994-04-06 Procede de triage concernant des agonistes de recepteurs

Publications (1)

Publication Number Publication Date
AU6556194A true AU6556194A (en) 1994-10-24

Family

ID=26723218

Family Applications (1)

Application Number Title Priority Date Filing Date
AU65561/94A Abandoned AU6556194A (en) 1993-04-07 1994-04-06 Method for screening for receptor agonists

Country Status (6)

Country Link
EP (1) EP0694078A4 (fr)
JP (1) JPH08512197A (fr)
AU (1) AU6556194A (fr)
BR (1) BR9406616A (fr)
CA (1) CA2160135A1 (fr)
WO (1) WO1994023068A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2161964C2 (ru) * 1994-08-22 2001-01-20 Эли Лилли Энд Компани Способ ингибирования (угнетения) эндометриального рака
AU6263996A (en) * 1995-06-07 1996-12-30 Ligand Pharmaceuticals Incorporated Method for screening for receptor agonists and antagonists
AU7074496A (en) 1995-09-18 1997-04-09 Ligand Pharmaceuticals Incorporated Ppar gamma antagonists for treating obesity
US5728534A (en) 1996-07-19 1998-03-17 New England Medical Center Hospitals, Inc. Methods for identifying cardiovascular therapeutic agents
US6692928B1 (en) 1996-07-19 2004-02-17 New England Medical Center Hospitals, Inc. Methods for identifying cardiovascular agents
EP1093362A1 (fr) 1998-06-12 2001-04-25 Ligand Pharmaceuticals Incorporated Traitement du cancer du sein resistant aux anti-oestrogenes avec des modulateurs de rxr
DE122008000018I1 (de) 2000-01-21 2008-08-14 Novartis Pharma Ag Zusammensetzungen bestehend aus Dipeptidylpeptidase-IV Inhibitoren und Antidiabetica
US7026484B2 (en) 2001-02-23 2006-04-11 Ligand Pharmaceuticals Incorporated Tricyclic androgen receptor modulator compounds and methods
EP1388352A1 (fr) 2002-08-08 2004-02-11 Laboratoires Fournier S.A. Utilisation d'un agoniste de PPAR-alpha pour traiter l'obesité associée au traitement avec un agonist de PPAR-gamma dans des patients
BRPI0413820A (pt) 2003-08-22 2006-10-24 Ligand Pharm Inc derivados de 6-cicloamino-2-quinolinona como compostos moduladores de receptor de androgênio
CN102935081B (zh) 2005-09-14 2015-03-04 武田药品工业株式会社 用于治疗糖尿病的二肽基肽酶抑制剂
WO2011041293A1 (fr) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Dérivés pyrazolo [1, 5—a] pyrimidines comme inhibiteurs de kinase 1 régulatrice de signal d'apoptose
ES2445917T3 (es) 2010-02-03 2014-03-06 Takeda Pharmaceutical Company Limited Inhibidores de quinasa 1 reguladora de la señal de apoptosis
WO2015059632A1 (fr) 2013-10-23 2015-04-30 Acadia Pharmaceuticals Inc. Traitement d'une maladie ou un trouble neurodégénératif
US20230132366A9 (en) 2018-11-26 2023-04-27 Denali Therapeutics Inc. Methods for treating dysregulated lipid metabolism

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071773A (en) * 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays

Also Published As

Publication number Publication date
CA2160135A1 (fr) 1994-10-13
EP0694078A4 (fr) 1997-06-25
WO1994023068A1 (fr) 1994-10-13
JPH08512197A (ja) 1996-12-24
BR9406616A (pt) 1996-02-06
EP0694078A1 (fr) 1996-01-31

Similar Documents

Publication Publication Date Title
Pham et al. Ligand-dependent and-independent function of the transactivation regions of the human estrogen receptor in yeast.
Goldberg et al. Activation of protein kinase C or cAMP‐dependent protein kinase increases phosphorylation of the c‐erbA‐encoded thyroid hormone receptor and of the v‐erbA‐encoded protein.
Tzukerman et al. Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions.
US5445941A (en) Method for screening anti-osteoporosis agents
Webster et al. The hormone-binding domains of the estrogen and glucocorticoid receptors contain an inducible transcription activation function
AU6556194A (en) Method for screening for receptor agonists
US5723291A (en) Methods for screening compounds for estrogenic activity
EP0629697A2 (fr) Matériael et méthodes de screening d'agents anti-ostéoporotiques
WO1996041013A1 (fr) Procedes de depistage d'agonistes et d'antagonistes de recepteurs
AU682398B2 (en) Methods for screening antiestrogen compounds
US20080014585A1 (en) Synergistic activation of regulatory elements by rel proteins and a steroid receptor
US6156723A (en) Compositions comprising inhibitors of estrogen response
JP2003526346A5 (fr)
Reese Jr Molecular actions of estrogen agonists and antagonists and their interaction with the human estrogen receptor
WO2000026232A1 (fr) Represseur de l'activite du recepteur des oestrogenes
Handel Novel mechanisms of action of progesterone receptor and progesterone antagonists
US6692928B1 (en) Methods for identifying cardiovascular agents
Zhuang Mechanistic analysis of estrogen receptor action using dominant negative mutants
Zhong Role of the conserved tyrosine 537 on hormone binding and stability in the human estrogen receptor
Borgo Luigi Cicatiello,† Raffaele Addeo,† Annarita Sasso, Lucia Altucci, Valeria Belsito Petrizzi, Raphaelle Borgo, Massimo Cancemi, Simona Caporali, Silvana Caristi, Claudio Scafoglio, Diana Teti, 2 Francesco Bresciani, Bruno Perillo, 3 and Alessandro Weisz1
Miller Selective utilization of ectopic epidermal growth factor receptor signaling in estrogen receptor positive breast cancer cells
Bonagura Functional characterization of androgen insensitivity syndrome: Mutant androgen receptor interaction with transcriptional coactivators
Katzenellenbogen et al. Cyclic AMP Modulation of Estrogen-Induced Effects: A Novel Mechanism for Hormonal Resistance in Breast Cancer
Rapiejko Characterization of point mutations of the ligand-binding domain of the human estrogen receptor
Giangrande Elucidation of the molecular mechanisms underlying the differential transcriptional activities of the two isoforms of the human progesterone receptor